Related Experiment Videos
Assessing the helping alliance and its impact in the treatment of opiate dependence
M A Belding1, M Y Iguchi, A R Morral
1Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia Veterans Affairs Medical Center 19104, USA.
Insights
The patient-counselor helping alliance (HA) in methadone maintenance treatment may not directly improve outcomes. A strong HA appears to be a marker of progress rather than a cause of reduced drug use.
Area of Science:
- Addiction medicine
- Psychotherapy research
- Clinical psychology
Background:
- The patient-counselor helping alliance (HA) is crucial in psychotherapy.
- Its role in methadone maintenance treatment (MMT) outcomes requires further investigation.
Purpose of the Study:
- To examine the relationship between the patient-counselor HA and treatment progress in MMT.
- To determine if HA predicts reductions in drug use, treatment retention, or psychiatric symptom improvement.
Main Methods:
- 57 patients undergoing MMT completed HA questionnaires at 1 and 3 months post-admission.
- Drug use was assessed via weekly urinalysis and 6-month self-report.
- Treatment retention and psychiatric symptoms were also monitored.
Main Results:
- Counselor-rated HA at 3 months predicted reduced drug use (urinalysis and self-report).
- HA was not associated with treatment retention or psychiatric symptom improvement.
- The predictive power of HA on drug use diminished when controlling for prior drug use, suggesting it may be a marker.
Conclusions:
- The findings suggest that a positive patient-counselor HA in MMT may reflect treatment progress rather than independently cause positive outcomes.
- The unique contribution of HA to predicting reduced drug use is questionable when accounting for prior substance use.
- Further research is needed to clarify the causal role of the therapeutic alliance in MMT outcomes.
Abstract:
This study assesses the relationship between the patient-counselor helping alliance (HA) and progress in methadone maintenance treatment. Questionnaire measures of HA were administered to 57 patients 1 and 3 months after admission. Three-month HA measures (especially counselors' ratings) predicted reductions in drug use as measured by weekly urinalysis results and 6-month self-report data. HA was unrelated to treatment retention or improvement in psychiatric symptomatology. Moreover, controlling for urinalysis results in the previous month rendered insignificant the correlations between 3-month HA and subsequent drug use. Thus, this evaluation of the HA's unique contribution to the prediction of outcome suggests that the development of a positive HA may be more a marker of treatment progress than a necessary precursor of positive outcomes in the methadone maintenance treatment setting.